A team of three researchers writing in the journal Nature say that by treating the metabolic and molecular causes of human aging, it would be possible to prevent multiple chronic diseases and help people stay healthy into their 70s and 80s.
Lead author Luigi Fontana, MD, PhD, professor of medicine and nutrition at Washington University and Brescia University said, "Heart failure doesn't happen all at once. It takes 30 or 40 years of an unhealthy lifestyle and activation of aging-related pathways from metabolic abnormalities such as high blood pressure, high cholesterol and type 2 diabetes to give a person heart failure in his 60s. So we propose using lifestyle interventions such as a personalized healthy diet and exercise program to down-regulate aging pathways so the patient avoids heart failure in the first place."
AdvertisementHis own research has highlighted potential benefits from dietary restriction in extending healthy life span. He has found that people who eat significantly fewer calories, while still getting optimal nutrition, have "younger," more flexible hearts. They also have significantly lower blood pressure, much less inflammation in their bodies and their skeletal muscles function in ways similar to muscles in people who are significantly younger.
Fontana and his co-authors also point out that several molecular pathways shown to increase longevity in animals also are affected by approved and experimental drugs, including rapamycin, an anticancer and organ-rejection drug, and metformin, a drug used to treat type 2 diabetes.
Numerous natural and synthetic molecules affect pathways shared by aging, diabetes and its related metabolic syndrome. Also, healthy diets and calorie restriction are known to help animals live up to 50 percent longer.
But it's been difficult to capitalize on research advances to stall aging in people. Fontana and his colleagues write that most clinicians don't realize how much already is understood about the molecular mechanisms of aging and their link to chronic diseases. And scientists don't understand precisely how the drugs that affect aging pathways work.
Fontana and his colleagues contend that the time is right for moving forward with preclinical and clinical trials of the most promising findings from animal studies. They also call for developing well-defined endpoints to determine whether work in animals will translate to humans. They are optimistic on that front because it appears that the nutrient-sensing and aging-related pathways in humans are very similar to those that have been targeted to help animals live longer and healthier lives.
But challenges abound. The most important change, they argue, is in mindset. Economic incentives in biomedical research and health care reward treating diseases more than promoting good health, they note.